Connect your AI

Bio-Techne TECH Diagnostics And Spatial Biology — Goodwill Acquired

Discontinued — last reported Q4 '24

Similar metrics at other companies

LHDiagnostics — Goodwill acquired, excluding measurement period adjustments

$146.6M—

RVTYDiagnostics — Goodwill

$1.86B-4.0%

LHDiagnostics — Goodwill

$5.61B—

RVTYDiagnostics — Goodwill, Acquisition

$0—

BIOClinical Diagnostics — Goodwill

$421.8M+1.3%

DHRDiagnostics — Goodwill

$6.96B+1.8%

Other financials

Income statement

Revenue$311.4M-1.5%

Gross profit$208.3M-2.9%

Operating income$75.5M+95.0%

Net income$51.0M+126%

EPS (diluted)$0.32+129%

Balance sheet

Cash & equivalents$209.8M+49.2%

Total debt$290.3M-31.4%

Total equity$2.1B+3.3%

Total assets$2.6B-3.5%

Cash flow

Operating cash flow$86.7M+111%

CapEx$9.1M-10.2%

Free cash flow$77.6M+150%

Valuation

Market cap$9.07B-11.8%

Enterprise value$9.15B-13.6%

P/E60.6×+13.6×

P/S7.5×-1.0×

Profitability

Gross margin65%-0.8pp

Operating margin14.2%-7.9pp

Net margin10.9%-6.7pp

FCF margin22.3%+4.0pp

Returns & leverage

Return on equity6.5%-3.9pp

Debt / equity0.1×-0.1×

Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The official record: Bio-Techne’s 10-K, filed August 22, 2025, on SEC EDGAR. View the filing →

Ask your AI about Bio-Techne's diagnostics and spatial biology — goodwill acquired.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bio-Techne's diagnostics and spatial biology — goodwill acquired?: Bio-Techne (TECH) reported diagnostics and spatial biology — goodwill acquired of $26.16M in Q2 2024.
What does diagnostics and spatial biology — goodwill acquired mean?: Records the amount of goodwill recognized on the balance sheet resulting from business acquisitions completed during the current reporting period. This metric highlights the company's inorganic growth strategy and the capital deployed to expand the diagnostics and spatial biology segment. It represents the premium paid for assets that do not have a specific identifiable fair value.